Telehealth company Ro raised $150 million from existing investors at a $7 billion valuation with plans to expand its dermatology offering.
WHO: Ro is a direct-to-patient healthcare company providing high-quality, affordable healthcare without the need for insurance. Ro is the only company to seamlessly connect telehealth, in-home care, diagnostics, labs, and pharmacy services nationwide. This is enabled by Ro's vertically integrated platform that powers a personalized, end-to-end healthcare experience from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has facilitated more than eight million digital healthcare visits in nearly every county in the United States, including 98% of primary care deserts.
WHY: Ro will use the newly raised capital to strengthen its position in direct-to-patient care—a model of healthcare that uses technology to reduce costs, expand access, and empower patients to choose and pay for the healthcare they want and need.
IN THEIR OWN WORDS: Zachariah Reitano, co-founder and CEO of Ro, said, "In less than five years, Ro has become the only company to combine nationwide telemedicine, in-home care, diagnostics, labs, and pharmacy services. With this funding, Ro can accelerate our pursuit of revolutionizing healthcare by building accessible, impactful, and trusted care that people want. This year, that means debuting a unified, single-branded care experience for our patients and further enabling other healthcare companies to benefit from the patient-centric technology and services we've built."
DETAILS:
